1.02 -0.06 (-5.56%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.36 | 1-year : | 1.59 |
Resists | First : | 1.16 | Second : | 1.36 |
Pivot price | 1 | |||
Supports | First : | 0.86 | Second : | 0.68 |
MAs | MA(5) : | 1.04 | MA(20) : | 0.97 |
MA(100) : | 0.65 | MA(250) : | 1.03 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 70.2 | D(3) : | 69.3 |
RSI | RSI(14): 57.6 | |||
52-week | High : | 2.38 | Low : | 0.43 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VIRX ] has closed below upper band by 44.4%. Bollinger Bands are 33.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 1.08 - 1.09 | 1.09 - 1.09 |
Low: | 0.97 - 0.97 | 0.97 - 0.98 |
Close: | 1.01 - 1.02 | 1.02 - 1.03 |
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Wed, 20 Mar 2024
Viracta Therapeutics CFO and COO Dan Chevallard resigns By Investing.com - Investing.com
Tue, 12 Mar 2024
Healthcare Stocks on the Move Tuesday: RGLS, LTRN, VIRX, GLSI, LEXX, CRBU, ASLN, VRPX - InvestorsObserver
Thu, 07 Mar 2024
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewswire
Thu, 07 Mar 2024
Sunesis: Q4 Earnings Snapshot - Houston Chronicle
Thu, 29 Feb 2024
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort ... - GlobeNewswire
Tue, 06 Feb 2024
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 39 (M) |
Shares Float | 25 (M) |
Held by Insiders | 2.8 (%) |
Held by Institutions | 53.1 (%) |
Shares Short | 683 (K) |
Shares Short P.Month | 650 (K) |
EPS | -1.33 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.33 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -41.5 % |
Return on Equity (ttm) | -128.6 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.28 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -40 (M) |
Levered Free Cash Flow | -22 (M) |
PE Ratio | -0.78 |
PEG Ratio | -0.1 |
Price to Book value | 3.09 |
Price to Sales | 0 |
Price to Cash Flow | -1.01 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |